Eisai/Pfizer Get U.S. FDA Complete Response For Alzheimer's Patch
This article was originally published in PharmAsia News
Executive Summary
Eisai Inc. announced April 25 that FDA has issued a "complete response" for the transdermal patch version of its best-selling drug Aricept (donepezil) for Alzheimer's disease